The study, sponsored by the Chinese PLA General Hospital, aims to evaluate the safety and feasibility of a novel allogenic gene-edited CAR-T cell therapy targeting CD19 and CD20 or CD22 in patients with relapsed or refractory B-cell malignancies. The dual specificity approach addresses the challenge of CD19 loss in tumor cells, potentially expanding the therapeutic window for CAR-T therapies in this patient population. Given the increasing prevalence of hematological malignancies and the limitations of current CAR-T therapies, this asset may capture significant market interest, particularly in regions with high unmet medical needs. The competitive landscape includes established CAR-T therapies like Kymriah and Yescarta, but the dual-targeting mechanism may provide a differentiated offering. Diligence should focus on regulatory pathways, manufacturing scalability, and potential partnerships for commercialization.